共 50 条
[21]
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
[J].
Litton, J. K.
;
Hurvitz, S. A.
;
Mina, L. A.
;
Rugo, H. S.
;
Lee, K-H
;
Goncalves, A.
;
Diab, S.
;
Woodward, N.
;
Goodwin, A.
;
Yerushalmi, R.
;
Roch, H.
;
Im, Y-H
;
Eiermann, W.
;
Quek, R. G. W.
;
Usari, T.
;
Lanzalone, S.
;
Czibere, A.
;
Blum, J. L.
;
Martin, M.
;
Ettl, J.
.
ANNALS OF ONCOLOGY,
2020, 31 (11)
:1526-1535

Litton, J. K.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Hurvitz, S. A.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Mina, L. A.
论文数: 0 引用数: 0
h-index: 0
机构:
Banner MD Anderson Canc Ctr, Gilbert, AZ USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Rugo, H. S.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Lee, K-H
论文数: 0 引用数: 0
h-index: 0
机构:
Seoul Natl Univ Hosp, Seoul, South Korea Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Goncalves, A.
论文数: 0 引用数: 0
h-index: 0
机构:
Inst Paoli Calmettes, Marseille, France Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Diab, S.
论文数: 0 引用数: 0
h-index: 0
机构:
Rocky Mt Canc Ctr, Littleton, CO USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Woodward, N.
论文数: 0 引用数: 0
h-index: 0
机构:
Mater Misericordiae Ltd, Mater Res Inst, Brisbane, Qld, Australia
Univ Queensland, Brisbane, Qld, Australia Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Goodwin, A.
论文数: 0 引用数: 0
h-index: 0
机构:
Concord Repatriat Gen Hosp, Med Oncol Dept, Concord, Australia Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Yerushalmi, R.
论文数: 0 引用数: 0
h-index: 0
机构:
Beilinson Med Ctr, Rabin Med Ctr, Petah Tiqwa, Israel Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Roch, H.
论文数: 0 引用数: 0
h-index: 0
机构:
Inst Univ Canc Toulouse, Inst Claudius Regaud, Toulouse, France Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Im, Y-H
论文数: 0 引用数: 0
h-index: 0
机构:
Samsung Med Ctr, Seoul, South Korea Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Eiermann, W.
论文数: 0 引用数: 0
h-index: 0
机构:
Interdisziplinares Onkol Zentrum Munchen, Munich, Germany Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Quek, R. G. W.
论文数: 0 引用数: 0
h-index: 0
机构:
Pfizer Inc, San Francisco, CA USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Usari, T.
论文数: 0 引用数: 0
h-index: 0
机构:
Pfizer Oncol, Milan, Italy Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Lanzalone, S.
论文数: 0 引用数: 0
h-index: 0
机构:
Pfizer Oncol, Milan, Italy Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Czibere, A.
论文数: 0 引用数: 0
h-index: 0
机构:
Pfizer Inc, Cambridge, MA USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Blum, J. L.
论文数: 0 引用数: 0
h-index: 0
机构:
Baylor Charles A Sammons Canc Ctr, US Oncol Network, Texas Oncol, Dallas, TX USA Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Martin, M.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Complutense, Dept Med, CIBERONC, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

Ettl, J.
论文数: 0 引用数: 0
h-index: 0
机构:
Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[22]
Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
[J].
Angell, Helen
;
Ros, Vidalba Rocher
;
Standifer, Nathan
;
Lai, Zhongwu
;
Gresty, Christopher
;
Delord, Jean-Pierre
;
De Jonge, Maja
;
Postel-Vinay, Sophie
;
Italiano, Antoine
;
Krebs, Matthew G.
;
Kaufman, Bella
;
Park, Yeon Hee
;
Domchek, Susan
;
Herbolsheimer, Pia
;
Hodgson, Darren
.
JOURNAL FOR IMMUNOTHERAPY OF CANCER,
2017, 5

Angell, Helen
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England AstraZeneca, Cambridge, England

Ros, Vidalba Rocher
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England AstraZeneca, Cambridge, England

Standifer, Nathan
论文数: 0 引用数: 0
h-index: 0
机构:
MedImmune, Mountain View, CA USA AstraZeneca, Cambridge, England

Lai, Zhongwu
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England AstraZeneca, Cambridge, England

Gresty, Christopher
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England AstraZeneca, Cambridge, England

Delord, Jean-Pierre
论文数: 0 引用数: 0
h-index: 0
机构:
Inst Claudius Regaud Oncopole, Toulouse, France AstraZeneca, Cambridge, England

De Jonge, Maja
论文数: 0 引用数: 0
h-index: 0
机构:
Erasmus MC Canc Inst, Rotterdam, Netherlands AstraZeneca, Cambridge, England

Postel-Vinay, Sophie
论文数: 0 引用数: 0
h-index: 0
机构:
Gustave Roussy Canc Campus, Villejuif, France AstraZeneca, Cambridge, England

Italiano, Antoine
论文数: 0 引用数: 0
h-index: 0
机构:
Inst Bergonie, Bordeaux, France AstraZeneca, Cambridge, England

Krebs, Matthew G.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Manchester, Manchester, Lancs, England
Christie NHS Fdn Trust, Manchester, Lancs, England AstraZeneca, Cambridge, England

Kaufman, Bella
论文数: 0 引用数: 0
h-index: 0
机构:
Sheba Med Ctr, Ramat Gan, Israel AstraZeneca, Cambridge, England

Park, Yeon Hee
论文数: 0 引用数: 0
h-index: 0
机构:
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea AstraZeneca, Cambridge, England

Domchek, Susan
论文数: 0 引用数: 0
h-index: 0
机构:
Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA AstraZeneca, Cambridge, England

Herbolsheimer, Pia
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Gaithersburg, MD USA AstraZeneca, Cambridge, England

Hodgson, Darren
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England AstraZeneca, Cambridge, England
[23]
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
[J].
Sun, Tao
;
Shi, Yanxia
;
Cui, Jiuwei
;
Yin, Yongmei
;
Ouyang, Quchang
;
Liu, Qiang
;
Zhang, Qingyuan
;
Chen, Yiding
;
Shao Zhimin
;
Wang, Shouman
;
Wang, Xiaojia
;
Tong, Zhongsheng
;
Zhong, Yahua
;
Yan, Min
;
Yan, Xi
;
Wang, Chuan
;
Yang, Haiyuan
;
Li, Miao
;
Xiang, Xiao
;
Xu, Binghe
.
JOURNAL OF CLINICAL ONCOLOGY,
2021, 39 (15)

Sun, Tao
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Shi, Yanxia
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Cui, Jiuwei
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Yin, Yongmei
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Ouyang, Quchang
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Liu, Qiang
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Zhang, Qingyuan
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Chen, Yiding
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Shao Zhimin
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Wang, Shouman
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Wang, Xiaojia
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Tong, Zhongsheng
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Zhong, Yahua
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Yan, Min
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Yan, Xi
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Wang, Chuan
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Yang, Haiyuan
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Li, Miao
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Xiang, Xiao
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

Xu, Binghe
论文数: 0 引用数: 0
h-index: 0
机构: Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[24]
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
[J].
Tutt, Andrew Nicholas James
;
Kaufman, Bella
;
Gelber, Richard D.
;
Mc Fadden, Eleanor
;
Goessl, Carsten Dietrich
;
Viale, Giuseppe
;
Arahmani, Amal
;
Fumagalli, Debora
;
Azim, Hatem Abdel
;
Wu, Wenting
;
Grocholewicz, Anna
;
Costantino, Joseph P.
;
Rastogi, Priya
;
Garber, Judy Ellen
;
Geyer, Charles E.
.
JOURNAL OF CLINICAL ONCOLOGY,
2015, 33 (15)

Tutt, Andrew Nicholas James
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Kaufman, Bella
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Gelber, Richard D.
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Mc Fadden, Eleanor
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Goessl, Carsten Dietrich
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Viale, Giuseppe
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Arahmani, Amal
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Fumagalli, Debora
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Azim, Hatem Abdel
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Wu, Wenting
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Grocholewicz, Anna
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Costantino, Joseph P.
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Rastogi, Priya
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Garber, Judy Ellen
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England

Geyer, Charles E.
论文数: 0 引用数: 0
h-index: 0
机构: Kings Coll London, Sch Med, London WC2R 2LS, England
[25]
BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)
[J].
Dalvi, T.
;
Gelmon, K. A.
;
Dent, R.
;
Pegram, M.
;
Loibl, S.
;
Tazir, Y.
;
Milner, A.
;
Lewis, J.
.
ANNALS OF ONCOLOGY,
2017, 28

Dalvi, T.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Gelmon, K. A.
论文数: 0 引用数: 0
h-index: 0
机构:
British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Dent, R.
论文数: 0 引用数: 0
h-index: 0
机构:
Duke NUS Med Sch, Div Med Oncol, Natl Canc Ctr Singapore, Singapore, Singapore AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Pegram, M.
论文数: 0 引用数: 0
h-index: 0
机构:
Stanford Womens Canc Ctr, Breast Canc Oncol Program, Palo Alto, CA USA AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Loibl, S.
论文数: 0 引用数: 0
h-index: 0
机构:
German Breast Grp, Med & Res, Neu Isenburg, Germany AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Tazir, Y.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Med Evidence & Observat Res, Wedel, Germany AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Milner, A.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Biostat & Informat Sci, Cambridge, England AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA

Lewis, J.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Global Med Dev, Cambridge, England AstraZeneca, Med Evidence & Observat Res, Gaithersburg, MD USA
[26]
LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation
[J].
Gelmon, K. A.
;
Walker, G. P.
;
Fisher, G. V.
;
McCutcheon, S. C.
.
ANNALS OF ONCOLOGY,
2018, 29

Gelmon, K. A.
论文数: 0 引用数: 0
h-index: 0
机构:
British Columbia Canc Agcy, Vancouver, BC, Canada British Columbia Canc Agcy, Vancouver, BC, Canada

Walker, G. P.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England British Columbia Canc Agcy, Vancouver, BC, Canada

Fisher, G. V.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England British Columbia Canc Agcy, Vancouver, BC, Canada

McCutcheon, S. C.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Cambridge, England British Columbia Canc Agcy, Vancouver, BC, Canada
[27]
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
[J].
Tutt, A.
;
Kaufman, B.
;
Garber, J.
;
Gelber, R.
;
McFadden, E.
;
Goessl, C.
;
Viale, G.
;
Geyer, C.
;
Zardavas, D.
;
Arahmani, A.
;
Fumagalli, D.
;
De Azambuja, E.
;
Ponde, N.
;
Herbolsheimer, P.
;
Wu, W.
;
Constantino, J.
;
Rastogi, P.
.
ANNALS OF ONCOLOGY,
2017, 28

Tutt, A.
论文数: 0 引用数: 0
h-index: 0
机构:
Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Kaufman, B.
论文数: 0 引用数: 0
h-index: 0
机构:
Sheba Med Ctr Tel HaShomer, Breast Med Oncol, Ramat Gan, Israel Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

论文数: 引用数:
h-index:
机构:

Gelber, R.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Ctr Canc Genet & Prevent, Boston, MA 02115 USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

McFadden, E.
论文数: 0 引用数: 0
h-index: 0
机构:
Frontier Sci, Stat, Inverness, Scotland Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Goessl, C.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Global Med Dev, Gaithersburg, MD USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Viale, G.
论文数: 0 引用数: 0
h-index: 0
机构:
Ist Europeo Oncol, Med Sch Pathol, Milan, Italy Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Geyer, C.
论文数: 0 引用数: 0
h-index: 0
机构:
Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Zardavas, D.
论文数: 0 引用数: 0
h-index: 0
机构:
Breast Int Grp, Brussels, Belgium Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Arahmani, A.
论文数: 0 引用数: 0
h-index: 0
机构:
Breast Int Grp, Brussels, Belgium Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Fumagalli, D.
论文数: 0 引用数: 0
h-index: 0
机构:
Breast Int Grp, Brussels, Belgium Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

De Azambuja, E.
论文数: 0 引用数: 0
h-index: 0
机构:
Breast Int Grp, Brussels, Belgium Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Ponde, N.
论文数: 0 引用数: 0
h-index: 0
机构:
Breast Int Grp, Brussels, Belgium Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Herbolsheimer, P.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Gaithersburg, MD USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Wu, W.
论文数: 0 引用数: 0
h-index: 0
机构:
AstraZeneca, Global Med Dev, Gaithersburg, MD USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Constantino, J.
论文数: 0 引用数: 0
h-index: 0
机构:
NRG Oncol, Stat, Philadelphia, PA USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England

Rastogi, P.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Pittsburgh Sch Hlth Sci, Div Hematol Oncol, Pittsburgh, PA USA Kings Coll London, Div Canc Studies, Breast Canc Now Res Unit, London, England
[28]
Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
[J].
Schwartzberg, Lee S.
;
Kiedrowski, Lesli A.
.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY,
2021, 13

Schwartzberg, Lee S.
论文数: 0 引用数: 0
h-index: 0
机构:
West Canc Ctr, 7945 Wolf River Blvd, Germantown, TN 38138 USA West Canc Ctr, 7945 Wolf River Blvd, Germantown, TN 38138 USA

Kiedrowski, Lesli A.
论文数: 0 引用数: 0
h-index: 0
机构:
Guardant Hlth Inc, Dept Med Affairs, Redwood City, CA USA West Canc Ctr, 7945 Wolf River Blvd, Germantown, TN 38138 USA
[29]
Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
[J].
Kuemmel, S.
;
Jackisch, C.
;
Mueller, V.
;
Schneeweiss, A.
;
Klawitter, S.
;
Lux, M. P.
.
ANNALS OF ONCOLOGY,
2017, 28

Kuemmel, S.
论文数: 0 引用数: 0
h-index: 0
机构:
Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany

Jackisch, C.
论文数: 0 引用数: 0
h-index: 0
机构:
Sana Clin Offenbach, Obstet & Gynecol, Offenbach, Germany Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany

Mueller, V.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, Hamburg, Germany Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany

Schneeweiss, A.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Hosp, Natl Ctr Tumor Dis NTC, Div Gynecol Oncol, Heidelberg, Germany Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany

Klawitter, S.
论文数: 0 引用数: 0
h-index: 0
机构:
Roche Pharma AG, Biostat & Epidemiol, Grenzach Wyhlen, Germany Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany

Lux, M. P.
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Hosp Erlangen, Univ Breast Ctr Franconia, OBGYN Dept, Erlangen, Germany Klinikum Essen Mitte, Canc Ctr Essen, Essen, Germany
[30]
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
[J].
Morganti, Stefania
;
Jin, Qingchun
;
Vincuilla, Julie
;
Buehler, Ryan
;
Ryan, Sean
;
Stokes, Samantha
;
Parker, Tonia
;
Mittendorf, Elizabeth A.
;
King, Tari A.
;
Weiss, Anna
;
Partridge, Ann H.
;
Bychkovsky, Brittany L.
;
Curigliano, Giuseppe
;
Tayob, Nabihah
;
Lin, Nancy U.
;
Garber, Judy E.
;
Tolaney, Sara M.
;
Lynce, Filipa
.
NPJ BREAST CANCER,
2024, 10 (01)

Morganti, Stefania
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Broad Inst MIT & Harvard, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Jin, Qingchun
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Vincuilla, Julie
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

论文数: 引用数:
h-index:
机构:

Ryan, Sean
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Stokes, Samantha
论文数: 0 引用数: 0
h-index: 0
机构:
Broad Inst MIT & Harvard, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Parker, Tonia
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Mittendorf, Elizabeth A.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Brigham & Womens Hosp, Dept Surg, Div Breast Surg, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

King, Tari A.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Brigham & Womens Hosp, Dept Surg, Div Breast Surg, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Weiss, Anna
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Brigham & Womens Hosp, Dept Surg, Div Breast Surg, Boston, MA USA
Univ Rochester, Med Ctr, Div Surg Oncol, Rochester, NY USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Partridge, Ann H.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Bychkovsky, Brittany L.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Dana Farber Canc Inst, Div Canc Genet & Prevent, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Curigliano, Giuseppe
论文数: 0 引用数: 0
h-index: 0
机构:
Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy
European Inst Oncol IRCCS, Milan, Italy Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

论文数: 引用数:
h-index:
机构:

Lin, Nancy U.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Garber, Judy E.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA
Dana Farber Canc Inst, Div Canc Genet & Prevent, Boston, MA USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

Tolaney, Sara M.
论文数: 0 引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USA Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

论文数: 引用数:
h-index:
机构: